{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T01:25:48Z","timestamp":1794446748863,"version":"4.9.1"},"reference-count":38,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2021,1,22]],"date-time":"2021-01-22T00:00:00Z","timestamp":1611273600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100008392","name":"Danish Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008392","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007405","name":"Danish Heart Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007405","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Copenhagen County Foundation"},{"name":"Herlev and Gentofte Hospital"},{"DOI":"10.13039\/501100002918","name":"Copenhagen University Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002918","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,3,21]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>With the current focus on lipoprotein(a) as a likely causal risk factor for cardiovascular disease and new drugs potentially on the market to lower lipoprotein(a) levels, the safety of lowering lipoprotein(a) to low levels becomes increasingly important. We tested whether low levels of lipoprotein(a) and corresponding LPA genotypes associate with major disease groups including cancers and infectious disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>We included 109\u00a0440 individuals from the Copenhagen General Population Study. For main World Health Organization International Classification of Diseases 10th edition chapter diseases, the only concordant association of low levels of lipoprotein(a) plasma levels and corresponding LPA genotypes with risk of disease was with low risk of diseases of the circulatory system. Furthermore, no concordant association of low levels of lipoprotein(a) plasma levels and corresponding LPA genotypes with the risk of any cancer (i.e. cancer subtypes combined) or infectious disease was seen. The hazard ratio for the risk of any cancer was 1.06 [95% confidence interval (CI): 0.97\u20131.15] for the first vs. the fourth quartile of lipoprotein(a), 1.02 (0.97\u20131.07) for the fourth vs. the first quartile of KIV-2 number of repeats, and 1.01 (0.96\u20131.07) for rs10455872 non-carriers vs. carriers. The corresponding hazard ratios for the risk of hospitalization for infection were 1.05 (95% CI: 0.99\u20131.10), 1.02 (0.98\u20131.07), and 0.97 (0.93\u20131.03), respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In a large, contemporary, general population cohort, apart from the well-established association with cardiovascular disease, low levels of lipoprotein(a) and corresponding LPA genotypes did not concordantly associate with any major disease groups including cancers and infections. There is no safety signal from our results to indicate that low levels of lipoprotein(a) are harmful.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/eurheartj\/ehaa1085","type":"journal-article","created":{"date-parts":[[2020,12,19]],"date-time":"2020-12-19T03:04:52Z","timestamp":1608347092000},"page":"1147-1156","source":"Crossref","is-referenced-by-count":71,"title":["Low lipoprotein(a) levels and risk of disease in a large, contemporary, general population study"],"prefix":"10.1093","volume":"42","author":[{"given":"Anne","family":"Langsted","sequence":"first","affiliation":[{"name":"Department of Clinical Biochemistry , Borgmester Ib Juuls Vej 73, opgang 7, Herlev 2730, Denmark"},{"name":"The Copenhagen General Population Study, Herlev and Gentofte Hospital, Copenhagen University Hospital , Borgmester Ib Juuls Vej 73, opgang 7, Herlev 2730, Denmark"},{"name":"Faculty of Health and Medical Sciences, University of Copenhagen, Blegdamsvej 3B, 2200 Copenhagen N , Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00f8rge G","family":"Nordestgaard","sequence":"additional","affiliation":[{"name":"Department of Clinical Biochemistry , Borgmester Ib Juuls Vej 73, opgang 7, Herlev 2730, Denmark"},{"name":"The Copenhagen General Population Study, Herlev and Gentofte Hospital, Copenhagen University Hospital , Borgmester Ib Juuls Vej 73, opgang 7, Herlev 2730, Denmark"},{"name":"Faculty of Health and Medical Sciences, University of Copenhagen, Blegdamsvej 3B, 2200 Copenhagen N , Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pia R","family":"Kamstrup","sequence":"additional","affiliation":[{"name":"Department of Clinical Biochemistry , Borgmester Ib Juuls Vej 73, opgang 7, Herlev 2730, Denmark"},{"name":"The Copenhagen General Population Study, Herlev and Gentofte Hospital, Copenhagen University Hospital , Borgmester Ib Juuls Vej 73, opgang 7, Herlev 2730, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,1,22]]},"reference":[{"key":"2022102514452858800_ehaa1085-B1","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1001\/jama.2009.1063","article-title":"Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. Emerging Risk Factors Collaboration","volume":"302","author":"Erqou","year":"2009","journal-title":"JAMA"},{"key":"2022102514452858800_ehaa1085-B2","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1161\/CIRCULATIONAHA.107.715698","article-title":"Extreme lipoprotein(a) levels and risk of myocardial infarction in the general population: the Copenhagen City Heart Study","volume":"117","author":"Kamstrup","year":"2008","journal-title":"Circulation"},{"key":"2022102514452858800_ehaa1085-B3","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1056\/NEJMoa1109034","article-title":"Genetic associations with valvular calcification and aortic stenosis","volume":"368","author":"Thanassoulis","year":"2013","journal-title":"N Engl J Med"},{"key":"2022102514452858800_ehaa1085-B4","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.jacc.2013.09.038","article-title":"Elevated lipoprotein(a) and risk of aortic valve stenosis in the general population","volume":"63","author":"Kamstrup","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"2022102514452858800_ehaa1085-B5","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.jacc.2019.03.524","article-title":"Elevated lipoprotein(a) and risk of ischemic stroke","volume":"74","author":"Langsted","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2022102514452858800_ehaa1085-B6","doi-asserted-by":"crossref","first-page":"2760","DOI":"10.1093\/eurheartj\/ehy902","article-title":"High lipoprotein(a) and high risk of mortality","volume":"40","author":"Langsted","year":"2019","journal-title":"Eur Heart J"},{"key":"2022102514452858800_ehaa1085-B7","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1001\/jama.2009.801","article-title":"Genetically elevated lipoprotein(a) and increased risk of myocardial infarction","volume":"301","author":"Kamstrup","year":"2009","journal-title":"JAMA"},{"key":"2022102514452858800_ehaa1085-B8","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1056\/NEJMoa0902604","article-title":"Genetic variants associated with Lp(a) lipoprotein level and coronary disease","volume":"361","author":"Clarke","year":"2009","journal-title":"N Engl J Med"},{"key":"2022102514452858800_ehaa1085-B9","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1056\/NEJMoa1905239","article-title":"Lipoprotein(a) reduction in persons with cardiovascular disease","volume":"382","author":"Tsimikas","year":"2020","journal-title":"N Engl J Med"},{"key":"2022102514452858800_ehaa1085-B10","first-page":"2753","volume-title":"Metabolic and Molecular Bases of Inherited Disease","author":"Utermann","year":"2006","edition":"2001st ed."},{"key":"2022102514452858800_ehaa1085-B11","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.atherosclerosis.2009.12.036","article-title":"Lipoprotein(a) and ischemic heart disease\u2013a causal association? A review","volume":"211","author":"Kamstrup","year":"2010","journal-title":"Atherosclerosis"},{"key":"2022102514452858800_ehaa1085-B12","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1093\/eurheartj\/ehz310","article-title":"Statin therapy increases lipoprotein(a) levels","volume":"41","author":"Tsimikas","year":"2020","journal-title":"Eur Heart J"},{"key":"2022102514452858800_ehaa1085-B13","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMoa1107579","article-title":"Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy","volume":"365","author":"Boden","year":"2011","journal-title":"N Engl J Med"},{"key":"2022102514452858800_ehaa1085-B14","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/S0140-6736(15)60158-1","article-title":"Cholesterol ester transfer protein inhibition by TA-8995 in patients with mild dyslipidaemia (TULIP): a randomised, double-blind, placebo-controlled phase 2 trial","volume":"386","author":"Hovingh","year":"2015","journal-title":"Lancet"},{"key":"2022102514452858800_ehaa1085-B15","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/j.jacl.2019.06.002","article-title":"Alirocumab efficacy and safety by race and ethnicity: analysis from 3 ODYSSEY phase 3 trials","volume":"13","author":"Ferdinand","year":"2019","journal-title":"J Clin Lipidol"},{"key":"2022102514452858800_ehaa1085-B16","doi-asserted-by":"crossref","first-page":"2567","DOI":"10.1161\/CIRCULATIONAHA.113.002432","article-title":"Lipoprotein apheresis in patients with maximally tolerated lipid-lowering therapy, lipoprotein(a)-hyperlipoproteinemia, and progressive cardiovascular disease: prospective observational multicenter study","volume":"128","author":"Leebmann","year":"2013","journal-title":"Circulation"},{"key":"2022102514452858800_ehaa1085-B17","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.jacc.2017.11.014","article-title":"NHLBI Working Group recommendations to reduce lipoprotein(a)-mediated risk of cardiovascular disease and aortic stenosis","volume":"71","author":"Tsimikas","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"2022102514452858800_ehaa1085-B18","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1373\/clinchem.2010.146779","article-title":"Lipoprotein(a) and risk of type 2 diabetes","volume":"56","author":"Mora","year":"2010","journal-title":"Clin Chem"},{"key":"2022102514452858800_ehaa1085-B19","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/S2213-8587(13)70064-0","article-title":"Lipoprotein(a) concentrations, isoform size, and risk of type 2 diabetes: a Mendelian randomisation study","volume":"1","author":"Kamstrup","year":"2013","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2022102514452858800_ehaa1085-B20","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1373\/clinchem.2017.276931","article-title":"High lipoprotein(a) and low risk of major bleeding in brain and airways in the general population: a Mendelian randomization study","volume":"63","author":"Langsted","year":"2017","journal-title":"Clin Chem"},{"key":"2022102514452858800_ehaa1085-B21","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1093\/ije\/dyh132","article-title":"Mendelian randomization: prospects, potentials, and limitations","volume":"33","author":"Smith","year":"2004","journal-title":"Int. J. Epidemiol"},{"key":"2022102514452858800_ehaa1085-B22","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/330113a0","article-title":"Plasma lipoproteins: teaching old dogmas new tricks","volume":"330","author":"Brown","year":"1987","journal-title":"Nature"},{"key":"2022102514452858800_ehaa1085-B23","doi-asserted-by":"crossref","first-page":"2761","DOI":"10.1016\/j.jacc.2016.10.033","article-title":"Phenotypic characterization of genetically lowered human lipoprotein(a) levels","volume":"68","author":"Emdin","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"2022102514452858800_ehaa1085-B24","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1194\/jlr.R071233","article-title":"Lipoprotein (a) as a cause of cardiovascular disease: insights from epidemiology, genetics, and biology","volume":"57","author":"Nordestgaard","year":"2016","journal-title":"J Lipid Res"},{"key":"2022102514452858800_ehaa1085-B25","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1007\/s10157-013-0875-8","article-title":"Causes and consequences of lipoprotein(a) abnormalities in kidney disease","volume":"18","author":"Kronenberg","year":"2014","journal-title":"Clin Exp Nephrol"},{"key":"2022102514452858800_ehaa1085-B26","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.ctrv.2007.02.006","article-title":"Lipoprotein[a] and cancer: anti-neoplastic effect besides its cardiovascular potency","volume":"33","author":"Lippi","year":"2007","journal-title":"Cancer Treat Rev"},{"key":"2022102514452858800_ehaa1085-B27","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s11789-017-0084-1","article-title":"Lipoprotein(a) and its role in inflammation, atherosclerosis and malignanciesz","volume":"12","author":"Orso","year":"2017","journal-title":"Clin Res Cardiol Suppl"},{"key":"2022102514452858800_ehaa1085-B28","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1515\/CCLM.2009.094","article-title":"Lipoprotein(a) level and its association with tumor stage in male patients with primary lung cancer","volume":"47","author":"Yang","year":"2009","journal-title":"Clin Chem Lab Med"},{"key":"2022102514452858800_ehaa1085-B29","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1111\/jop.12344","article-title":"Alteration of serum lipid profile and its prognostic value in head and neck squamous cell carcinoma","volume":"45","author":"Li","year":"2016","journal-title":"J Oral Pathol Med"},{"key":"2022102514452858800_ehaa1085-B30","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.canep.2014.07.013","article-title":"Significant association between hypolipoproteinemia(a) and lifetime risk of cancer: an autopsy study from a community-based Geriatric Hospital","volume":"38","author":"Mieno","year":"2014","journal-title":"Cancer Epidemiol"},{"key":"2022102514452858800_ehaa1085-B31","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1097\/CEJ.0b013e328359cba7","article-title":"Lipoprotein(a) plasma levels and the risk of cancer: the PRIME study","volume":"22","author":"Marrer","year":"2013","journal-title":"Eur J Cancer Prev"},{"key":"2022102514452858800_ehaa1085-B32","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1161\/01.ATV.20.4.1137","article-title":"Major reduction in plasma Lp(a) levels during sepsis and burns","volume":"20","author":"Mooser","year":"2000","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2022102514452858800_ehaa1085-B33","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1002\/hep.29096","article-title":"Apolipoprotein(a) inhibits hepatitis C virus entry through interaction with infectious particles","volume":"65","author":"Oliveira","year":"2017","journal-title":"Hepatology"},{"key":"2022102514452858800_ehaa1085-B34","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1053\/euhj.1999.1755","article-title":"The proatherogenic properties of lipoprotein(a) may be enhanced through the formation of circulating immune complexes containing Chlamydia pneumoniae-specific IgG antibodies","volume":"21","author":"Glader","year":"2000","journal-title":"Eur Heart J"},{"key":"2022102514452858800_ehaa1085-B35","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1093\/ndt\/gfv428","article-title":"Dialysis Study I. Lipoprotein(a) concentrations, apolipoprotein(a) isoforms and clinical endpoints in haemodialysis patients with type 2 diabetes mellitus: results from the 4D Study","volume":"31","author":"Kollerits","year":"2016","journal-title":"Nephrol Dial Transplant"},{"key":"2022102514452858800_ehaa1085-B36","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1161\/ATVBAHA.119.312951","article-title":"Lipoprotein(a)-Lowering by 50 mg\/dL (105 nmol\/L) May Be Needed to Reduce Cardiovascular Disease 20% in Secondary Prevention: a Population-Based Study","volume":"40","author":"Madsen","year":"2020","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2022102514452858800_ehaa1085-B37","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J"},{"key":"2022102514452858800_ehaa1085-B38","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1007\/s11883-019-0792-8","article-title":"Antisense Oligonucleotides Targeting Lipoprotein(a)","volume":"21","author":"Langsted","year":"2019","journal-title":"Curr Atheroscler Rep"}],"container-title":["European Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/42\/12\/1147\/46626770\/ehaa1085.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/42\/12\/1147\/46626770\/ehaa1085.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,25]],"date-time":"2022-10-25T13:27:16Z","timestamp":1666704436000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartj\/article\/42\/12\/1147\/6173737"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,22]]},"references-count":38,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2021,1,22]]},"published-print":{"date-parts":[[2021,3,21]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/ehaa1085","relation":{},"ISSN":["0195-668X","1522-9645"],"issn-type":[{"value":"0195-668X","type":"print"},{"value":"1522-9645","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,3,21]]},"published":{"date-parts":[[2021,1,22]]}}}